A clean bill of health


Byotrol reveals the results of six-month study within a hospital environment on the control of MRSA

Byotrol is a UK-based company that has developed and patented a new antimicrobial technology based around safety, ease-of-use and delivery of a complete anti-microbial solution. The technology is available for application within markets where microbial control and elimination of such hazards and threats is paramount, including:

  • Healthcare
  • Hospitals & cleanroom
  • Food & drink
  • Processing & manufacturing
  • Technical & commercial
  • Fungal growth, building fabric
The microbial control technology, which shares the company name, Byotrol, combines the effect of chemical and physical forces to kill micro-organisms and provides lasting inhibition to biofilm formation. The technology uses a selection of known biocides and associates them by non-chemical bonds to an inert polymer structure that is strongly hydrophobic. This combination when applied forms a monolayer to both wet or dry surfaces.

Using this technology, Byotrol was able to reduce the presence of the superbug methicillin-resistant Staphylococcus aureus (MRSA) by 75% at the Glasgow Royal Infirmary, in Scotland. The company conducted a six-month study at the Infirmary to measure the effects of the anti-microbial technology in combating the spread of MRSA within a working hospital ward environment.

The study was staged in two ward areas within Vascular Surgery at the Infirmary, which because of the nature of conditions and patients treated had the potential for a high incidence of MRSA infection. One of the wards was cleaned with Byotrol and the other with existing cleaning agents.

The independently supervised study showed that daily cleaning of the ward’s high contact surfaces – door handles, tables, television handsets, patient contact systems and bed rails, (representing a small fraction of the total surfaces within the ward) – with Byotrol’s patented biocide resulted in a significant reduction in the incidence of MRSA.

The cleaning regimen, which required no special equipment or extra resource, was practised for four months and the incidence of MRSA was shown to have been reduced by 75% against the pre-trial condition of the ward. During this phase there were test periods with no incidence of MRSA.

Furthermore, the number of hospital-acquired cases of MRSA was seen to be 50% higher in the area of the ward where a conventional disinfectant was used compared with that where Byotrol was used. The reduction experienced was achieved as a result of Byotrol’s residual antimicrobial action on surfaces, even after it has dried.

The study was independently supervised by Curtis Gemmell, Professor of Bacterial Infection and Epidemiology at the University of Glasgow, who worked closely with the hospital’s Vascular Surgery team. Professor Gemmell is also a director of the Scottish MRSA Reference Laboratory and an appointed adviser to Byotrol on the requirements of the UK’s National Health Service (NHS) and control of infection in healthcare.

This independent study has demonstrated the effectiveness of Byotrol in a working hospital environment. The product was used by the existing cleaning staff, with no risk or disturbance to patients or healthcare professionals and with no requirement for expensive equipment. The directors believe that the results of the study further pave the way for the company to achieve significant sales into the healthcare sector.

Following the success of the Glasgow Infirmary trial, Byotrol has entered the NHS and independent healthcare sector through an agreement with Synergy Healthcare. This leading provider of outsourced medical services to both the UK and the Netherlands has an annualised turnover of over £130m and over 2,500 employees.

Synergy has been providing sterile services in the UK since 1996 and is the UK’s largest provider of decontamination and sterile services for surgical instruments. The company operates 15 facilities and processing some 40m instruments each year.

The contract gives Synergy exclusive sales and distribution rights to Byotrol’s technology in the UK healthcare market. In addition Synergy will market, sell and distribute the Assure product range to the NHS and Byotrol’s existing healthcare customers. In the UK, and will assume responsibility for supplying products containing Byotrol to existing healthcare and care home users.

Synergy will also be purchasing Byotrol concentrates for use in the manufacture of anti-microbial products.

Byotrol has also entered into a distribution agreement with DBM Holdings (DBM) to supply the Assure product range into the UK care homes market. Based in Edinburgh, DBM supplies products to healthcare and retail markets, with a particular focus on independent care home operators throughout the UK.

The Assure range has been specifically developed for the care homes sector and comprises disinfectant sprays for use in living areas, kitchens and bathrooms, cleaning and sanitising wipes, and a hand sanitising mousse. The company’s patented technology has been proven, through extensive testing, to be effective in eradicating and controlling a wide range of organisms such as MRSA, C. difficile and E. coli. Because Byotrol remains active after it has dried, providing anti-microbial protection for extended periods after application, it is able to tackle the practical problems of odours and spoilage caused by microbe activity.

Byotrol is non-toxic to humans and does not require any specialist equipment or alteration to existing cleaning regimens to be effective. A further advantage is its ultra low alcohol content compared with competing products, which means it does not dry or irritate the skin when used as a hand sanitiser as part of infection control procedures.

Byotrol has been awarded CE Mark status, enabling it to supply its biocide products for use in disinfectant sprays, wipes and foams throughout Europe. The CE Mark indicates that products comply with the relevant requirements of European health, safety and environmental protection legislation. This represents a major milestone for the company and allows the technology to be sold into the healthcare industry on a pan-European basis. It also means it can sell to UK-based companies with European operations that want to deploy a single hygiene regime across their business.

The company has also been granted a patent in China for its biocide technology. The patent will enable the company to pursue a number of global opportunities it is currently working on, with the confidence that its products will enjoy patent protection within China.

It currently has a number of other patents pending in the Far East, including Singapore and the granting of the Chinese patent follows successful applications in the UK and South Africa, which were granted in 2005 and 2004 respectively. There are currently patents pending for the technology in numerous other countries including the US, Canada and Australia and the company expects these to be granted in due course.

The company is engaged in discussions with a number of global companies regarding deployment of its technology and is pleased to be able to announce it has secured significant contracts in the industrial and food processing sectors.

Becker Industrial Coatings, one of the world’s leading industrial coatings manufacturers has launched a range of anti-microbial coatings containing Byotrol under the BeckryShield brand name. The launch follows extensive trials undertaken to test the efficacy of the technology and the BeckryShield range offers effective anti-microbial protection for up to two years. The company will receive revenues from the sale of concentrate and a royalty on sales achieved.

The company has recently shipped its first customer order to Gold Kist, one of America’s largest poultry processing companies, which is using Byotrol technology as part of its hygiene regime initially in its South Carolina processing plant.

Securing the patent in China and winning significant contracts are the latest in a series of milestones for the company. Based on work currently being undertaken and progress to date, the board is increasingly optimistic about future prospects for growth in our chosen market sectors.